Cargando…

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

BACKGROUND: KW-2478 is a novel non-ansamycin Hsp90 inhibitor with modest single-agent activity in relapsed/refractory myeloma but which shows synergistic antimyeloma activity with bortezomib (BTZ) in preclinical studies. This study determined the safety, preliminary clinical activity, and pharmacoki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavenagh, J, Oakervee, H, Baetiong-Caguioa, P, Davies, F, Gharibo, M, Rabin, N, Kurman, M, Novak, B, Shiraishi, N, Nakashima, D, Akinaga, S, Yong, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672925/ https://www.ncbi.nlm.nih.gov/pubmed/28873084 http://dx.doi.org/10.1038/bjc.2017.302

Ejemplares similares

Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
por: Ishii, T, et al.
Publicado: (2012)

Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
por: Yong, K, et al.
Publicado: (2016)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
por: Suzuki, Rikio, et al.
Publicado: (2014)

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole
por: Umehara, Hiroshi, et al.
Publicado: (2018)

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
por: Usmani, Saad Z, et al.
Publicado: (2010)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

2478. Surveillance of antibacterial resistance among clinical isolates from hospitals in Shanghai: results of 2018
por: Yang, Yang, et al.
Publicado: (2019)

PB2478: ASCIMINIB INDUCES ERYTHROPOIESIS IN CHRONIC MYELOID LEUKEMIA CELLS THROUGH DIFFERENTIATION AND NOT BY SELECTION
por: Hassan, Hammad, et al.
Publicado: (2023)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021)

Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity
por: Schwartz, Gary K., et al.
Publicado: (2016)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
por: Lee, Keun-Wook, et al.
Publicado: (2005)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Hsp-90 and the biology of nematodes
por: Him, Nik AIIN, et al.
Publicado: (2009)

Mechanisms of Hsp90 regulation
por: Prodromou, Chrisostomos
Publicado: (2016)

Regulatory Mechanisms of Hsp90
por: Prodromou, Chrisostomos
Publicado: (2017)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Role of HSP90 in Cancer
por: Birbo, Bereket, et al.
Publicado: (2021)

Organismal Roles of Hsp90
por: van Oosten-Hawle, Patricija
Publicado: (2023)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Cell surface heparan sulfate proteoglycans are involved in the binding of Hsp90α and Hsp90β to the cell plasma membrane
por: Snigireva, Anastasiya V, et al.
Publicado: (2015)

The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
por: Chang, Cheng, et al.
Publicado: (2023)

Milk Exosome-Derived MicroRNA-2478 Suppresses Melanogenesis through the Akt-GSK3β Pathway
por: Bae, In-Seon, et al.
Publicado: (2021)

2478. Trends in antibiotic resistance for nine pathogens in the US Veterans Affairs Healthcare System from 2007 to 2022
por: Pham, Thi Mui, et al.
Publicado: (2023)

Myeloma therapy: pursuing the plasma cell
por: Cavenagh, J
Publicado: (2010)

Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
por: Park, Sangkyu, et al.
Publicado: (2019)

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma
por: Salmenniemi, Urpu, et al.
Publicado: (2012)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
por: Cerchione, Claudio, et al.
Publicado: (2016)

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice
por: Hulin, Cyrille, et al.
Publicado: (2018)

Effect of EPA on Hsp90 and GRα protein expression in multiple myeloma drug-resistant cells
por: Wu, Shenghao, et al.
Publicado: (2021)

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
por: Richardson, Paul G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ncf9nnt74vdl2487k9j5hq6er4